Institut Jules Bordet shared a post on LinkedIn:
“[ESMO BREAST 2025]
The Jules Bordet Institute was widely represented at ESMO Breast 2025, the major European congress on breast cancer.
Here is an overview of the key presentations of our teams – far from exhaustive as our involvement has been so rich!
Results of the ROSALINE neoadjuvant study for lobular cancers
Final survival data from the APHINITY adjuvant study in amplified HER2 cancer (>11 years follow-up)
Discussion on the future of immunotherapy in endocrine-dependent cancers, with a focus on the Neo-CheckRay study
Speakers at two satellite symposia on genetic testing and biomarkers
Several posters were also presented by our medical fellows
Congratulations to all those involved for their scientific and human contribution.”
More posts featuring Jules Bordet Institute.
